Intellia Therapeutics (NTLA)

• Market cap: $845M
• 1 day: -2.86%
• 5 days: -11.40%
• 1 month: -19.13%
• 3 months: -28.48%
• 6 months: -60.29%
• Year to date: -33.22%
• 1 year: -70.34%
• 5 years: -35.65%
• 10 years: -63.08%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

33% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 49

5.09% more ownership

Funds ownership: 92.39% [Q3] → 97.47% (+5.09%) [Q4]

4% more funds holding

Funds holding: 280 [Q3] → 291 (+11) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

39% less capital invested

Capital invested by funds: $1.93B [Q3] → $1.17B (-$758M) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 35% upside
• Avg. target: $33 306% upside
• High target: $68 733% upside

11 analyst ratings

• positive: 7 64%
• neutral: 4 36%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 60 / 182 met price target	268% upside $30	Buy Initiated	5 Mar 2025
Truist Securities Joon Lee 55% 1-year accuracy 22 / 40 met price target	513% upside $50	Buy Maintained	4 Mar 2025
Barclays Gena Wang 24% 1-year accuracy 7 / 29 met price target	219% upside $26	Overweight Maintained	28 Feb 2025
Citigroup David Lebowitz 42% 1-year accuracy 8 / 19 met price target	72% upside $14	Neutral Maintained	28 Feb 2025
Wells Fargo Yanan Zhu 0% 1-year accuracy 0 / 16 met price target	513% upside $50	Overweight Maintained	28 Feb 2025